Fig. 2From: Prospective evaluation of NGS-based liquid biopsy in untreated late stage non-squamous lung carcinoma in a single institutionImpact of liquid biopsy NGS testing on treatment selection. Each column represents one patient. Tissue NGS was possible in 16/24 patients and PD-L1 expression was assessed in 22/24 patients. The percentage of tumor cells in the tissue is indicated as a number for each patient in the tissue NGS row. Treatment selection was based on the PD-L1 expression from tissue sections and the detection of targetable EGFR mutations. While the PD-L1 expression in patient #3 would have allowed the initiation of first-line treatment with the anti-PD1 antibody pembrolizumab, there were clinical reasons prohibiting the treatment and consequently the patient was initially treated with chemotherapy. ADK adenocarcinoma, NOS non-small cell lung cancer not otherwise specifiedBack to article page